Save the date in your event calendar: Join and learn about the new era of cancer care at the ICPO Theranostics Virtual Summit, Nov 14 -15, 2024
June 27, 2024 00:00 ET
|
ICPO Foundation
Save the date in your event calendar: Join and learn about the new era of cancer care at the ICPO Theranostics Virtual Summit, Nov 14 -15, 2024 The ICPO Foundation offers a world-class scientific...
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI
June 25, 2024 09:00 ET
|
Qure.ai Technologies Limited
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI.
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
June 25, 2024 08:07 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Veterinary Oncology Market to Hit $1,563.7 Million by 2031, at a CAGR of 11.6%, says Coherent Market Insights
June 25, 2024 07:15 ET
|
CMI
Burlingame, June 25, 2024 (GLOBE NEWSWIRE) -- The global Veterinary Oncology Market size was valued at US$ 724.9 Million in 2024 and is expected to reach US$ 1,563.7 Million by 2031, growing at a...
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
June 24, 2024 12:41 ET
|
PRISM MarketView
Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
June 24, 2024 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global...
Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
June 21, 2024 08:05 ET
|
Starton Therapeutics
100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to those associated with Revlimid®No grade 3 or greater...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024 07:00 ET
|
Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the...
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024 10:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer...
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024 08:45 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally....